On Demand: The Future of Cell Therapy Development and Delivery
Sponsored by Precision ADVANCE, this Endpoints webinar convened leading advanced therapy experts to discuss the future of cell therapy development and delivery. This discussion was moderated by John Khoury: EVP (Project Farma), and included insights from Chris McDonald: Global Head of Tech Ops (Kite Pharma), Mark Frattini: CMO (Cellectis), Jason Foster: CEO & ED (Ori Biotech), and Phil Cyr: SVP (Precision Value & Health).
Conference: CAR-TCR Summit, 2023
Precision will be at this year’s CAR-TCR Summit August 29 – September 1, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization of cell therapies.
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
- Precision ADVANCE will hold a welcome reception on August 29, 2023, at 5:30 pm.
- Project Farma will be facilitating a Manufacturing track panel discussion “Keys to Success for a Commercial – Ready Cell Therapy Facility” on August 30, 2023, 4:30 – 5:00 pm.
- Precision ADVANCE will be facilitating an Early-Stage Clinical Strategy track panel discussion “Strategies for Successful Clinical Development of Cell Therapies” on August 30, 2023, 4:30 – 5:00 pm.
- Precision ADVANCE will have a plenary speaking position “The Journey of Commercializing Cell Therapies” on August 31, 2023, 8:05 – 8:50 am.
Connect with our Advanced Therapy experts
- Visit us at booth 90 in the exhibition area
- Schedule in-person or virtual meetings with one of our experts
- Attend our ADVANCE-sponsored Welcome Reception on August 29, 2023, at 5:30 PM ET
White Paper: mRNA Innovation Is Revolutionizing Disease Prevention
The first FDA approved mRNA product was decades in the making, following many iterations throughout history the first mRNA vaccine in the US was brought to life. This achievement delivered aid to patients and healthcare providers during the most critical public health crisis in recent years. Since then, researchers have been operating at incredible speeds to develop more novel mRNA treatment options for patients, across many indications.
In this white paper, Anshul Mangal, President of Project Farma & Precision ADVANCE and Chad Salisbury, Senior Vice President of Project Farma (PF), discuss the mRNA revolution and its impact on the future of disease prevention and treatment.
White Paper: Moving Clinical Development Forward in 2023
In today’s cell and gene therapy landscape, there are over 1,400 companies striving to move their products forward into clinic—a critical step in commercializing these groundbreaking treatments. Clinical development is a complex endeavor and the path to market requires careful consideration of factors ranging from chemistry, manufacturing, and controls (CMC) and regulatory strategy to study design, CRO selection, and clinical trial diversity.
White Paper: The Price is Right: Cell and Gene Therapy Approvals and Market Access in 2023
Starting health economic evidence development and market access planning as early as possible in clinical development for a cell and gene therapy is important demonstrating the value to payers and health technology appraisal (HTA) organizations. In a dynamic regulatory and market access landscape, balancing the requirements of regulators and the expectations of payors can be challenging since there is no one-size-fits-all approach.